Statin Lipophilicity and the Risk of Incident Heart Failure: A Retrospective Study
Authors/Creators
- 1. Senior Resident, Department of Medicine, GMCH, Purnia
Description
Background: Cholesterol-lowering statin therapy is a mainstay in the fight against cardiovascular disease. There has been some debate over whether or not statin lipophilicity increases the risk of heart failure in recent studies. The purpose of this retrospective cohort study is to look at the association between statin lipophilicity and incident heart failure. Methods: Electronic health records were used for retrospective cohort research. All participants had to be 18 or older, and there had to be a history of statin use. Statins were divided into two groups: highly lipophilic and less lipophilic. Heart failure rates were evaluated during a mean of three years of follow-up. Hazard ratios and 95% confidence intervals were calculated using a statistical model that accounted for confounding variables. Results: Overall, the rate of heart failure was slightly more significant among those taking highly lipophilic statins (6.7 cases per 1,000 person-years) compared to those taking less lipophilic statins (5.0 cases per 1,000 person-years) in our research of 200 patients. The risk of heart failure was trending upwards with highly lipophilic statins, although this difference did not achieve statistical significance (Hazard Ratio: 1.32, 95% CI: 0.89 – 1.96). Conclusion: Consistent with previous research, this study emphasises the nuanced connection between statin lipophilicity and heart failure risk. While the observed trend was not statistically significant, the complicated nature of the association calls for additional investigation in larger, more representative cohorts. In the absence of definitive evidence, clinicians should take individual patient features into account when administering statins.
Abstract (English)
Background: Cholesterol-lowering statin therapy is a mainstay in the fight against cardiovascular disease. There has been some debate over whether or not statin lipophilicity increases the risk of heart failure in recent studies. The purpose of this retrospective cohort study is to look at the association between statin lipophilicity and incident heart failure. Methods: Electronic health records were used for retrospective cohort research. All participants had to be 18 or older, and there had to be a history of statin use. Statins were divided into two groups: highly lipophilic and less lipophilic. Heart failure rates were evaluated during a mean of three years of follow-up. Hazard ratios and 95% confidence intervals were calculated using a statistical model that accounted for confounding variables. Results: Overall, the rate of heart failure was slightly more significant among those taking highly lipophilic statins (6.7 cases per 1,000 person-years) compared to those taking less lipophilic statins (5.0 cases per 1,000 person-years) in our research of 200 patients. The risk of heart failure was trending upwards with highly lipophilic statins, although this difference did not achieve statistical significance (Hazard Ratio: 1.32, 95% CI: 0.89 – 1.96). Conclusion: Consistent with previous research, this study emphasises the nuanced connection between statin lipophilicity and heart failure risk. While the observed trend was not statistically significant, the complicated nature of the association calls for additional investigation in larger, more representative cohorts. In the absence of definitive evidence, clinicians should take individual patient features into account when administering statins.
Files
IJPCR,Vol15,Issue11,Article6.pdf
Files
(782.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:31301a6d374f33926c0ff51c1ec0f938
|
782.0 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-10-30
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue11,Article6.pdf
- Development Status
- Active
References
- 1. J. A. Wong, D. Conen, J. S. Healey, and L. S. Johnson, Modifiable risk factors predict incident atrial fibrillation and heart failure, Open Heart, 2020; 7:1. 2. A.Douros et al., Kidney measures and risk of incident heart failure among older adults, JACC: Heart Failure, 2023. 3. L. M. Stevens, E. Linstead, J. L. Hall, and D. P. Kao, Association between coffee intake and Incident Heart Failure Risk, Circulation: Heart Failure, 2021;14:2. 4. Squire, Measurement of circulating natriuretic peptides to identify community‐based patients at risk of incident heart failure — should we?, European Journal of Heart Failure, 2019; 21(4): 460–461. 5. R. C. Block et al., Predicting risk for incident heart failure with omega-3 fatty acids, JACC: Heart Failure, 2019; 7(8): 651–661. 6. H. K. Gaggin and A. Abboud, Prediction of incident heart failure, JACC: Heart Failure, 2020; 8(5): 412–414. 7. D. L. Mann, Incident heart failure in chronic inflammatory diseases, JACC: Heart Failure, 2020; 8(6): 499–500. 8. R. Golbus et al., Statin intensity and risk for cardiovascular events after Heart Transplantation, ESC Heart Failure, 2020; 7(5): 2074–2081. 9. M. Zuin, G. Rigatelli, L. Roncon, G. Pasquetto, and C. Bilato, Risk of incident heart failure after COVID-19 recovery: A systematic review and meta-analysis, Heart Failure Reviews, 2022; 28(4): 859–864. 10. T. Imran, A. Wong, S. Schneeweiss, and R. J. Desai, Statin lipophilicity and the risk of incident heart failure, Cardiology, 2020; 145(6): 375–383. 11. M. Kou et al., Degree of Joint Risk Factor Control and incident heart failure in hypertensive patients, JACC: Heart Failure, 2023; 11(6): 678–688. 12. N. Cauwenberghs, F. Haddad, and T. Kuznetsova, Association of subclinical heart maladaptation with the pooled cohort equations to prevent heart failure risk score for incident heart failure, JAMA Cardiology, 2021; 6(2): 214. 13. Y. Kim, J. Choi, S. G. Kim, and N. H. Kim, Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: Population based Cohort Study, Cardiovascular Diabetology, 2022; 21(1). 14. P. P. Toth and M. K. Palmer, High risk US adults with untreated hyperlipidaemia enhances: Estimated reduction in cardiovascular events with Statin Treatment, European Heart Journal, Supplement_2, 2020;41. 15. Tent, Bempedoic acid benefits statin-intolerant patients at high cardiovascular risk, Medicom Conference Report ACC. 2023.